Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: A multicountry retrospective chart review

Peter Mohr, Felix Kiecker, Virtudes Soriano, Olivier Dereure, Karmele Mujika, Philippe Saiag, Jochen Utikal, Rama Koneru, Caroline Robert, Florencia Cuadros, Matias Chacón, Rodrigo U. Villarroel, Yana G. Najjar, Lisa Kottschade, Eva M. Couselo, Roy Koruth, Annie Guérin, Rebecca Burne, Raluca Ionescu-Ittu, Maurice PerrinjaquetJonathan S. Zager

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    8 Citations (Scopus)

    Résumé

    Aim: To describe treatment patterns among patients with stage III melanoma who underwent surgical excision in years 2011-2016, and assess outcomes among patients who subsequently received systemic adjuvant therapy versus watch-and-wait. Methods: Chart review of 380 patients from 17 melanoma centers in North America, South America and Europe. Results: Of 129 (34%) patients treated with adjuvant therapy, 85% received interferon α-2b and 56% discontinued treatment (mostly due to adverse events). Relapse-free survival was significantly longer for patients treated with adjuvant therapy versus watch-and-wait (hazard ratio = 0.63; p < 0.05). There was considerable heterogeneity in adjuvant treatment schedules and doses. Similar results were found in patients who received interferon-based adjuvant therapy. Conclusion: Adjuvant therapies with better safety/efficacy profiles will improve clinical outcomes in patients with stage III melanoma.

    langue originaleAnglais
    Numéro d'articleMMT33
    journalMelanoma Management
    Volume6
    Numéro de publication4
    Les DOIs
    étatPublié - 1 janv. 2019

    Contient cette citation